Interview, Presentation, Other
How to treat covid-19
- The SARS-CoV-2 virus, identified in January, shares structural similarities with the 2003 SARS outbreak and coronaviruses known since the 1960s, providing scientists with a foundational understanding of its biology despite the novel strain.
- The virus replicates by entering lung cells via spike proteins, releasing RNA, and hijacking cellular machinery to produce up to 1,000 new particles through a specific gene called replicase.
- Scientists target the replicase system for treatment because healthy human cells do not replicate RNA, allowing for potential virus destruction without harming human cells.
- Developing novel drugs from scratch is estimated to take months to years, prompting a strategic shift toward repurposing existing, safety-validated medications to accelerate treatment availability.
- Remdesivir, originally developed to treat Ebola, targets the replicase system; its molecular structure mimics RNA building blocks, causing the virus's replication machinery to fail.
- Colectra, an HIV medication used during the 2003 SARS outbreak, targets enzymes that process viral proteins and is currently being tested for similar efficacy against SARS-CoV-2.
- The World Health Organization launched a global "megatrial" in March to test Remdesivir, Colectra, and the anti-malarial drug chloroquine.
- President Donald Trump has advocated for hydroxychloroquine (a chloroquine derivative) as a potential "game changer," claiming immediate availability despite a lack of clinical evidence supporting its efficacy in patients.
- While laboratory studies suggest chloroquine may inhibit viral entry and reproduction, there is currently no strong evidence that it effectively treats COVID-19 in human patients.
- The WHO trial aims to detect marginal therapeutic benefits and minor side effects by testing on a large population, which could significantly reduce the duration of infection.
- Reducing the average hospital stay by five days could alleviate critical strain on health systems, allowing existing ventilator and personnel resources to treat more patients.
- While an effective vaccine is the definitive long-term solution (estimated at 1.5 to 2 years away), repurposed drugs offer immediate potential to manage the pandemic's acute phase.